{"id":"NCT01033747","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study","officialTitle":"A 5-year Open Label, Non-comparative Extension to a Randomized, Open-label, Phase IIa Study to Evaluate Safety, Tolerability and the Effects on Liver Iron Concentration of Repeated Doses of 10 and 20 mg/kg/Day of Deferasirox in Comparison With 40 mg/kg/Day Deferoxamine in Patients With Transfusion-dependent Iron Overload","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2003-02","primaryCompletion":"2008-01","completion":"2008-01","firstPosted":"2009-12-16","resultsPosted":"2011-08-11","lastUpdate":"2011-08-11"},"enrollment":70,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Liver Iron Overload"],"interventions":[{"type":"DRUG","name":"Deferasirox","otherNames":[]},{"type":"DRUG","name":"Deferasirox","otherNames":[]}],"arms":[{"label":"Deferasirox","type":"EXPERIMENTAL"},{"label":"Deferasirox Crossover","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the safety and the effects on liver iron of Deferasirox when given for a long treatment period in patients with transfusion dependent iron overload.","primaryOutcome":{"measure":"The Relative Change From Baseline in Liver Iron Content (LIC) After Prolonged Use of Deferasirox","timeFrame":"Baseline to 7 Years","effectByArm":[{"arm":"Deferasirox","deltaMin":-21.9,"sd":47.11},{"arm":"Deferasirox Crossover","deltaMin":-23.1,"sd":33.38}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":4,"countries":["Italy"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":51},"commonTop":["Cough","Pyrexia","Pharyngitis","Back pain","Headache"]}}